3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
20
Active not recruiting
11
Terminated
3
Not yet recruiting
2
Withdrawn
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Interventions
Cyclophosphamide
1488
Cisplatin
1410
Paclitaxel
1316
Radiotherapy
1259
Carboplatin
1247
Gemcitabine
1214
Docetaxel
1110
Bevacizumab
1029
Fluorouracil
894
Doxorubicin
786
Dexamethasone
746
Rituximab
719
Capecitabine
716
Oxaliplatin
700
pembrolizumab
673
Etoposide
673
Irinotecan
634
Filgrastim
621
Cytarabine
584
Leucovorin
578
Nivolumab
557
Vincristine
510
Prednisone
474
Cetuximab
464
Bortezomib
457
Erlotinib Hydrochloride
456
Trastuzumab
448
Methotrexate
437
Lenalidomide
426
Pemetrexed
419
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Interventional
×
iberdomide
×
Clear all
NCT03310619
2024-04-04
PLATFORM
Celgene
Phase 1/2
Completed
62 enrolled
41 charts